MAIA Biotechnology hits enrollment milestones in THIO-101 and THIO-104
MAIA completed Part C enrollment in its THIO-101 Phase 2 study and reached 65% of the 2026 enrollment target for the pivotal THIO-104 Phase 3 study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.